Discover our top picks for must-attend sessions at the World EPA Congress 2025 in Amsterdam. Enhance your understanding of core topics with our recommended pre-reading materials
Read More
Discover Sophie Streeton’s career journey and her decision to join Mtech Access. Learn about her early experiences in the Global Market Access Team. Sophie leverages her expertise in health policy, medical writing, and market access.
We are delighted to announce that Clare Foy (Director – Global Market Access), Hannah Palin (Director – Local Market Access), and Calum Jones (Associate Director – Health Economics) will be...
Read More
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In the final part...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 3 of...
Read More
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 2 of...
Read More
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions to help improve patient access. In Part 1, we will...
Read More
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
We’re delighted to announce that we will be exhibiting at ISPOR Europe in Barcelona over the 18th–20th November 2024. Mtech Access experts will be joined by our colleagues from across Petauri, including...
Read More
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How...
Read More
